Home » Clinical Trials » Medical Areas
Therapeutic Areas: Gastroenterology
Disease Category: Crohn's Disease

Trial Information

Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

A Phase IIIb, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderately to Severely Active Crohn's Disease

The primary objective of the study is to evaluate efficacy of Certolizumab Pegol in inducing a clinical response in patients with moderately to severe Crohn's disease as compared with placebo based on CDAI score at week 6.

Inclusion Criteria:

• male/female
• 18 - 75 years inclusive
• diagnosis of Crohn's disease confirmed
• active disease confirmed
• on a stable dose of concomitant medication

Exclusion Criteria:

• previous participation in a certolizumab pegol study
• general exclusion as common for studies in this indication

UCB Clinical Trial Call Center
Located in:
Chesterfield MI
Phone: +1-877-822-9493

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.